SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ogilvie, P. Articles by Uguccioni, M. Search for Related Content PubMed PubMed Citation Articles by Ogilvie, P. Articles by Uguccioni, M. Related Collections Phagocytes Chemokines, Cytokines, and Interleukins Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 April 2001, Vol. 97, No. 7, pp. 1920-1924 CHEMOKINES Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5 Patricia Ogilvie, Giuseppe Bardi, Ian Clark-Lewis, Marco Baggiolini, and Mariagrazia Uguccioni From the Institute for Research in Biomedicine, Bellinzona, Switzerland; Theodor Kocher Institute, University of Bern, Bern, Switzerland; Biochemical Research Center, University of British Columbia, Vancouver, Canada.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Eotaxin is a potent inducer of eosinophil chemotaxis and was considered as a selective ligand of the CC chemokine receptor 3 (CCR3), which is expressed on eosinophils, basophils, and Th2 lymphocytes. This study shows that eotaxin also interacts with CCR2 and CCR5 and can, thus, affect the responses of monocytes, which express both receptors. In human monocytes pretreatment with eotaxin decreased responsiveness to MCP-1, a selective ligand for CCR2, as well as to RANTES and MIP-1, which bind to CCR5. Similar effects were obtained with transfected cells expressing CCR2 or CCR5, but here a difference became apparent: Eotaxin triggered CCR5 at a concentration of 100 nM but not CCR2 even at 1 µM, suggesting an antagonistic effect on this receptor. In agreement with this observation, eotaxin induced internalization of CCR5 but not of CCR2 in human monocytes and transfected cells. Binding studies showed that eotaxin displaces 125 I-MCP-1 from monocytes in a concentration-dependent manner, and functional experiments showed that eotaxin inhibits MCP-1-induced chemotaxis and enzyme release. The results demonstrate that eotaxin is a CCR5 agonist and a CCR2 antagonist. The present findings suggest a role of eotaxin in the fine-tuning of cellular responses occurring at sites of allergic inflammation, in which both MCP-1 and eotaxin are produced. (Blood. 2001;97:1920-1924) © 2001 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Eotaxin was originally described as a potent and selective stimulus for eosinophil leukocytes inducing eosinophil migration in vitro and accumulation in vivo.1,2 These effects were shown to be mediated via chemokine receptor 3 (CCR3) that is highly expressed on eosinophils, basophils, and Th2 lymphocytes3-7 and, thus, mainly involved in allergic inflammation.8,9 Pathologic conditions, especially reactions that are dominated by Th2-type cytokines, were found to induce the expression of eotaxin10-12 and MCP-1 in several tissues.13-15 It was also reported that eosinophils secrete MCP-1 after stimulation with C5a, suggesting a mechanism for the production of this chemokine in infiltrates elicited by eotaxin.16 In addition to eosinophils, basophils, and Th2 lymphocytes, which are typically found in allergic inflammations and express CCR3, these infiltrates also contain monocytes that lack CCR3.17 Starting from the observation that eotaxin elicits changes in intracellular free calcium ([Ca++]i) and chemotaxis in human blood monocytes, we studied its effects on chemokine receptors known to occur in these cells, namely CCR1, CCR2, CCR5, and CXCR4. In this study, we show that eotaxin binds to CCR2 and CCR5, inducing opposite effects: antagonism on CCR2 and agonistic activities on CCR5. Our data indicate that eotaxin has a wider pathophysiologic role than previously assumed and may regulate monocyte responses during allergic inflammation.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Reagents All chemokines were synthesized as described.18 Monoclonal phycoerythrin (PE)-conjugated anti-CCR2 antibody, secondary antibodies, and isotype-matched immunoglobulins were purchased from R&D Systems (London, United Kingdom). Anti-CCR3 (clone 7B11)17 and anti-CCR5 (clone 5C7)19 antibodies were kindly provided by LeukoSite Inc (Cambridge, MA). Cells Monocytes (90% to 95% purity with 5% to 10% contaminating lymphocytes) were isolated from buffy coats of donor blood (Central Laboratory of the Swiss Red Cross, Bern, Switzerland) by centrifugation on Ficoll-Paque and Percoll gradients.20 For some experiments, monocytes were cultured overnight under standard conditions in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 10% nonessential amino acids, 1 mM sodium pyruvate, 0.05 mM -mercaptoethanol, 50 U/mL penicillin, 50 mg/mL streptomycin, and 2 mM glutamine (all from GIBCO BRL, Rockville, MD). The cells were detached from the dishes by incubation for 10 minutes on ice with 10 mM EGTA in phosphate-buffered saline (PBS), followed by 10 minutes at 37°C in 10 mM EDTA, and finally washed twice in PBS. Murine pre-B 300-19 cells stably expressing human CCR1, CCR2b, or CCR5 were obtained by transfection. The corresponding receptor complementary DNAs (cDNAs) were cloned into the SmaI/XbaI site of Srpuro (kindly provided by Dr F. Arenzana-Seisdedos, Institute Pasteur, Paris, France). The cells (5 × 106) were transfected by electroporation with 20 µg cDNA. Positive clones were selected in the presence of 1.5 µg/mL puromycin (Sigma, St. Louis, MO) and tested for chemokine responsiveness by monitoring [Ca++]i changes. Expression of CCR2b and CCR5 was also assessed by flow cytometry. Functional assays Chemotaxis was assayed in 48-well chambers (Neuro Probe, Cabin John, MD) by using polyvinylpyrrolidone-free polycarbonate Nucleopore membranes with 5 µm pores. N-acetyl--D-glucosaminidase release was assayed in monocytes as described previously.21 [Ca++]i changes were assessed in Fura-2-loaded cells.22 Receptor desensitization was determined by monitoring [Ca++]i changes in response to sequential stimulation with chemokines at 90-second intervals. Chemokine receptor expression and internalization Chemokine receptor expression in freshly isolated or cultured monocytes was analyzed by flow cytometry (FACScan, Becton Dickinson, San Jose, CA). The cells were incubated for 20 minutes with 0.1% human immunoglobulin G (IgG; Sandoglobulin; Novartis, Basel, Switzerland) in FACS buffer (2% FCS, 0.1% sodium azide in PBS), washed with FACS buffer, and then incubated for 30 minutes in FACS buffer with PE-conjugated anti-CCR2b, or anti-CCR3 or anti-CCR5, followed by a PE-conjugated goat antimouse antibody. Isotype-matched immunoglobulins were used as control. For determination of chemokine-induced receptor internalization, the cells were incubated for 45 minutes at 37°C with 1 µM eotaxin, MCP-1, or RANTES in FACS buffer without sodium azide before staining. Controls were performed under the same conditions at 4°C. The chemokines used did not affect antibody binding to the receptors. Receptor binding MCP-1 was iodinated with the Bolton Hunter reagent (Amersham Pharmacia Biotech, Uppsala, Sweden) according to the manufacturer's instructions. For competition binding studies, freshly isolated monocytes or CCR2b-transfected cells (4 × 106) in 120 µL RPMI-1640 containing 20 mM HEPES, 1% bovine serum albumin (BSA), pH 7.1 were incubated on ice for 90 minutes with 0.8 nM 125I-MCP-1 in the presence of increasing concentrations of unlabeled MCP-1 or eotaxin. The cells were then pelleted by centrifugation through 6% BSA in PBS, and the cell-bound radioactivity was determined by gamma-counting. The data were analyzed with PRISM software (GraphPad Software, San Diego, CA), using nonlinear regression in a one-binding-site model.     Results Top Abstract Introduction Materials and methods Results Discussion References Eotaxin acts on human monocytes As shown in Figure 1, eotaxin induced [Ca++]i changes in human monocytes. Responses were significant at concentrations of 300 nM or higher. After pretreatment with eotaxin, monocytes showed a decreased responsiveness to MCP-1, RANTES, and MIP-1 (Figure 1A), suggesting that eotaxin interacts with CCR2, the receptor for MCP-1, and with CCR5 that binds RANTES and MIP-1. Flow cytometric analysis of our preparations confirmed former evidence by Heath et al17 that monocytes do not express CCR3, the eotaxin receptor (data not shown). Figure 1B shows the [Ca++]i changes obtained when eotaxin was applied after pretreatment of the cells with one of the other chemokines. Ca++ mobilization by eotaxin was virtually abrogated by pretreatment with RANTES or MIP-1 but was not affected by pretreatment with MCP-1, suggesting that eotaxin acts via CCR5 but not via CCR2. Further experiments were performed with pre-B cells transfected with single human chemokine receptors known to be expressed on monocytes. Eotaxin was inactive on cells expressing CCR2b but decreased the responsiveness to MCP-1 (Figure 2A). In contrast, eotaxin induced a [Ca++]i rise in cells expressing CCR5 (Figure 2B). The rate of the [Ca++]i rise (percentage of FURA-2 saturation per second) was calculated. Table 1 summarizes the quantitative effects of pretreatment of the cells with one chemokine on the rate of the [Ca++]i rise induced by a second chemokine. The data are presented as relative values (percentage of control without pretreatment). To rule out the involvement of unidentified eotaxin-triggered receptors on the transfected cells as well as further chemokine receptors expressed on monocytes, namely CCR1 or CXCR4, cells expressing these receptors and untransfected 300-19 pre-B cells were analyzed and failed to respond to eotaxin up to the concentration of 1 µM (data not shown). These results indicate that eotaxin acts on monocytes via CCR5 and is an antagonist for CCR2. View larger version (18K): [in this window] [in a new window]   Figure 1. Eotaxin-induced [Ca++]i changes in monocytes. FURA-2-loaded monocytes were stimulated sequentially at 90-second intervals with 1 µM eotaxin followed by 10 nM MCP-1, 30 nM RANTES, or 10 nM MIP-1 (A) or vice versa (B), and [Ca++]i-dependent fluorescence changes were recorded. The tracings are representative of 2 to 4 independent experiments performed under identical conditions with cells from different donors. View larger version (15K): [in this window] [in a new window]   Figure 2. [Ca++]i changes in CCR2- and CCR5-transfected cells. Murine pre-B cells stably expressing human CCR2 or CCR5 were loaded with FURA-2, and [Ca++]i-dependent fluorescence changes were recorded after sequential stimulation with 1 µM eotaxin and 10 nM MCP-1 (for CCR2-expressing cells, A) or with 1 nM MIP-1 (for CCR5-expressing cells, B). Controls were run under the same conditions, using buffer instead of eotaxin. The tracings are representative of 2 independent experiments with each cell line.                                View this table: [in this window] [in a new window]   Table 1. Effect of chemokine pretreatment of monocytes and transfected cells expressing CCR2 or CCR5 Eotaxin-induced receptor internalization Chemokines with agonistic activity, in contrast to antagonists, induce the internalization of their receptors. The surface expression of CCR2 and CCR5 was determined on monocytes by flow cytometry before and after treatment with 1 µM eotaxin. As shown in Figure 3, eotaxin markedly decreased the level of CCR5 but did not influence the level of CCR2. Eotaxin-dependent CCR5 internalization was obtained in monocytes that were cultured overnight to enhance CCR5 expression prior to the experiment. The uptake of CCR5 but not of CCR2 was also observed when pre-B-cell transfectants expressing one or the other receptor were treated with eotaxin, whereas the total amount of each receptor detected by a combined intracellular and surface staining remained unchanged (data not shown). Together, these findings support the suggestion that eotaxin is an antagonist for CCR2 and an agonist for CCR5. View larger version (27K): [in this window] [in a new window]   Figure 3. Chemokine-induced CCR2 and CCR5 internalization on monocytes. Monocytes immediately after isolation (A) or cultured overnight (B) were treated with 1 µM eotaxin (thick line), the agonists (thin line) MCP-1 (A) or RANTES (B), or medium alone (broken line) for 60 minutes, stained with anti-CCR2 (A) or anti-CCR5 (B), and analyzed by flow cytometry. The histograms show the fluorescence intensity of relative cell number. Tracings are representative of 3 experiments performed with monocytes from different donors. Eotaxin is a CCR2 antagonist The effects of eotaxin were further explored by receptor binding and functional studies. Eotaxin competed for the binding of 125I-MCP-1 on monocytes and CCR2b-transfected cells (Figure 4). The ligand displacement curves were parallel to those obtained with unlabeled MCP-1, but the affinity of eotaxin was about 2 orders of magnitude lower than that of the CCR2 selective agonist. This difference is in agreement with the moderate potency of eotaxin as inhibitor of [Ca++]i mobilization induced by MCP-1. Migration and enzyme release assays were performed to assess further the effects of eotaxin on monocyte functions. Pretreatment of monocytes with eotaxin inhibited MCP-1-elicited chemotaxis and N-acetyl--D-glucosaminidase release in a concentration-dependent manner with half-maximal effects between 100 and 300 nM (Figure 5). In agreement with the former evidence, eotaxin was devoid of agonistic activity. The competition for MCP-1 binding and the inhibition of MCP-1-induced responses, which were obtained in a similar concentration range, indicate again that eotaxin is a CCR2 antagonist. View larger version (13K): [in this window] [in a new window]   Figure 4. 125I-MCP-1 binding competition on monocytes and CCR2-transfected cells. Monocytes (A) or CCR2-transfected cells (B) were incubated on ice for 90 minutes with 0.8 nM 125I-MCP-1 in the presence of increasing concentrations of unlabeled MCP-1 () or eotaxin (). The cells were then pelleted by centrifugation through 6% BSA in PBS, and cell-bound radioactivity was counted. The curves (means of duplicate values) are representative of 1 of 4 experiments performed with monocytes from different donors and 3 experiments performed with CCR2 transfectants. View larger version (22K): [in this window] [in a new window]   Figure 5. Inhibition of CCR2-dependent chemotaxis (A,B) and enzyme release (C,D). (A) MCP-1-induced chemotaxis of monocytes in the presence () or absence () of 300 nM eotaxin. (B) Concentration-dependent inhibition of monocyte chemotaxis in response to 1 nM MCP-1 by eotaxin. (C) MCP-1 () or eotaxin () induced N-acetyl--D-glucosaminidase release in cytochalasin B-treated monocytes. (D) Concentration-dependent inhibition of N-acetyl--D-glucosaminidase release in cytochalasin B-treated monocytes in response to 10 nM MCP-1 by eotaxin. Each panel shows mean values of 3 experiments performed with monocytes from different donors (bars indicate SEM).     Discussion Top Abstract Introduction Materials and methods Results Discussion References In this study, we show that eotaxin, a presumed selective agonist for CCR3, acts as a competitive antagonist on CCR2 and as an agonist on CCR5. The apparent affinity of eotaxin to both receptors is moderate (ie, up to 2 orders of magnitude less than its affinity to CCR3). Both effects, however, are concentration dependent, and the antagonism toward CCR2 is sufficient to reduce the main functional responses of monocytes, chemotaxis and enzyme release to minimal levels. Our observation that eotaxin stimulates CCR5-bearing cells is in agreement with recently reported data by Blanpain et al23 on transfected cells, showing that eotaxin binds to CCR5. Binding or activities of eotaxin on CCR2 have not been reported before. The present results indicate that eotaxin has potential activities beyond the recruitment of cells expressing CCR3, namely eosinophils,3,4 Th2 lymphocytes,6,7 and possibly basophils5 to sites of allergic inflammation and certain parasitic infestations. Eotaxin was originally considered a major mediator of pathology in allergic conditions and a prime target for therapeutic intervention.8 However, it was found that the so-called eotaxin receptor, CCR3, recognizes a large number of CC chemokines including MCP-2, MCP-3, MCP-4, RANTES, eotaxin-2, and eotaxin-3,24 and we now show that eotaxin also binds, albeit with lower affinity, to CCR2 and CCR5. Inhibition of the interaction of eotaxin with CCR3 was considered as a promising therapeutic strategy for allergic reactions. Despite the present evidence for interaction of eotaxin with other chemokine receptors, blockade of CCR3 still appears a worthy goal of therapy. CCR2 and CCR5, like CCR3, are receptors for inflammatory chemokines. They are both expressed on monocytes, macrophages, and interleukin 2-activated T lymphocytes, and CCR2 is additionally found on basophils. Ligands that activate CCR2 (ie, MCP-1, MCP-2, MCP-3, and MCP-4) have been characterized as major stimuli for release of enzymes by monocytes and natural killer cells21,25 and of histamine and leukotrienes by basophils.5 Owing to its antagonistic function on CCR2, eotaxin inhibits the release of inflammatory enzymes and possibly leukotrienes and histamine and thus displays anti-inflammatory effects. In this perspective eotaxin can be regarded as a chemokine with a dual activity in chemokine-driven inflammation.     Acknowledgments We thank Andrea Blaser for expert technical assistance and Dr Pius Loetscher for useful discussion. This work was also supported by the Helmut Horten Foundation.     Footnotes Submitted July 10, 2000; accepted November 22, 2000. Supported by grant 31-055996.98 from the Swiss National Science Foundations to M.B. and by grant OG8/1-1 from the Deutsche Forschungsgemeinschaft to P.O. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Mariagrazia Uguccioni, Institute for Research in Biomedicine, 6500 Bellinzona, Switzerland; e-mail: mariagrazia.uguccioni{at}irb.unisi.ch.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ. The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun. 1993;197:1167-1172[CrossRef][Medline] [Order article via Infotrieve]. 2. Forssmann U, Uguccioni M, Loetscher P, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med. 1997;185:2171-2176[Abstract/Free Full Text]. 3. Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A, Springer MS. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med. 1996;183:2349-2354[Abstract/Free Full Text]. 4. Ponath PD, Qin SX, Post TW, et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med. 1996;183:2437-2448[Abstract/Free Full Text]. 5. Uguccioni M, Mackay CR, Ochensberger B, et al. High expression of the chemokine receptor CCR3 in human blood basophilsrole in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest. 1997;100:1137-1143[Medline] [Order article via Infotrieve]. 6. Gerber BO, Zanni MP, Uguccioni M, et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol. 1997;7:836-843[CrossRef][Medline] [Order article via Infotrieve]. 7. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science. 1997;277:2005-2007[Abstract/Free Full Text]. 8. Baggiolini M. Eotaxin: a VIC (very important chemokine) of allergic inflammation? J Clin Invest. 1996;97:587[Medline] [Order article via Infotrieve]. 9. Gutierrez-Ramos JC, Lloyd C, Gonzalo JA. Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. Immunol Today. 1999;20:500-504[CrossRef][Medline] [Order article via Infotrieve]. 10. Mochizuki M, Bartels J, Mallet AI, Christophers E, Schröder JM. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol. 1998;160:60-68[Abstract/Free Full Text]. 11. Teran LM, Mochizuki M, Bartels J, et al. Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J Respir Cell Mol Biol. 1999;20:777-786[Abstract/Free Full Text]. 12. Doucet C, Brouty-Boyé D, Pottin-Clémenceau C, Canonica GW, Jasmin C, Azzarone B. Interleukin (IL)4 and IL-13 act on human lung fibroblastsimplication in asthma. J Clin Invest. 1998;101:2129-2139[Medline] [Order article via Infotrieve]. 13. Rollins BJ, Pober JS. Interleukin-4 induces the synthesis and secretion of MCP-1/JE by human endothelial cells. Am J Pathol. 1991;138:1315-1319[Abstract]. 14. Lukacs NW, Chensue SW, Smith RE, et al. Production of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 by inflammatory granuloma fibroblasts. Am J Pathol. 1994;144:711-718[Abstract]. 15. Flesch IEA, Wandersee A, Kaufmann SHE. IL-4 secretion by CD4+ NK1+ T cells induces monocyte chemoattractant protein-1 in early listeriosis. J Immunol. 1997;159:7-10[Abstract]. 16. Izumi S, Hirai K, Miyamasu M, et al. Expression and regulation of monocyte chemoattractant protein-1 by human eosinophils. Eur J Immunol. 1997;27:816-824[Medline] [Order article via Infotrieve]. 17. Heath H, Qin SX, Rao P, et al. Chemokine receptor usage by human eosinophilsthe importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest. 1997;99:178-184[Medline] [Order article via Infotrieve]. 18. Clark-Lewis I, Moser B, Walz A, Baggiolini M, Scott GJ, Aebersold R. Chemical synthesis, purification, and characterization of two inflammatory proteins, neutrophil activating peptide 1 (interleukin-8) and neutrophil activating peptide 2. Biochemistry. 1991;30:3128-3135[CrossRef][Medline] [Order article via Infotrieve]. 19. Wu LJ, LaRosa G, Kassam N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med. 1997;186:1373-1381[Abstract/Free Full Text]. 20. Colotta F, Peri G, Villa A, Mantovani A. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells, I: Effectors belong to the monocyte-macrophage lineage. J Immunol. 1984;132:936-944[Abstract]. 21. Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 and MIP-1 on human monocytes. Eur J Immunol. 1995;25:64-68[Medline] [Order article via Infotrieve]. 22. von Tscharner V, Prod'hom B, Baggiolini M, Reuter H. Ion channels in human neutrophils activated by a rise in free cytosolic calcium concentration. Nature. 1986;324:369-372[CrossRef][Medline] [Order article via Infotrieve]. 23. Blanpain C, Migeotte I, Lee B, et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood. 1999;94:1899-1905[Abstract/Free Full Text]. 24. Loetscher P, Moser B, Baggiolini M. Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol. 2000;74:127-180[Medline] [Order article via Infotrieve]. 25. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Activation of NK cells by CC chemokineschemotaxis, Ca2+ mobilization, and enzyme release. J Immunol. 1996;156:322-327[Abstract]. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. H. Schirmer, N. van Royen, P. D. Moerland, J. O. Fledderus, J. P. Henriques, R. J. van der Schaaf, M. M. Vis, J. Baan Jr, K. T. Koch, A. J.G. Horrevoets, et al. Local cytokine concentrations and oxygen pressure are related to maturation of the collateral circulation in humans. J. Am. Coll. Cardiol., June 9, 2009; 53(23): 2141 - 2147. [Abstract] [Full Text] [PDF] V. Levina, B. M. Nolen, A. M. Marrangoni, P. Cheng, J. R. Marks, M. J. Szczepanski, M. E. Szajnik, E. Gorelik, and A. E. Lokshin Role of Eotaxin-1 Signaling in Ovarian Cancer Clin. Cancer Res., April 15, 2009; 15(8): 2647 - 2656. [Abstract] [Full Text] [PDF] Z. Zhang, G. Cherryholmes, A. Mao, C. Marek, J. Longmate, M. Kalos, R. P. ST. Amand, and J. E. Shively High Plasma Levels of MCP-1 and Eotaxin Provide Evidence for an Immunological Basis of Fibromyalgia Experimental Biology and Medicine, September 1, 2008; 233(9): 1171 - 1180. [Abstract] [Full Text] [PDF] J. H. Cox, R. A. Dean, C. R. Roberts, and C. M. Overall Matrix Metalloproteinase Processing of CXCL11/I-TAC Results in Loss of Chemoattractant Activity and Altered Glycosaminoglycan Binding J. Biol. Chem., July 11, 2008; 283(28): 19389 - 19399. [Abstract] [Full Text] [PDF] K. J. Haley, M. E. Sunday, Y. Porrata, C. Kelley, A. Twomey, A. Shahsafaei, B. Galper, L. A. Sonna, and C. M. Lilly Ontogeny of the eotaxins in human lung Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L214 - L224. [Abstract] [Full Text] [PDF] A. Mori, K. Ogawa, K. Someya, Y. Kunori, D. Nagakubo, O. Yoshie, F. Kitamura, T. Hiroi, and O. Kaminuma Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists Int. Immunol., August 1, 2007; 19(8): 913 - 921. [Abstract] [Full Text] [PDF] S. Main, R. Handy, J. Wilton, S. Smith, L. Williams, L. D. Fou, J. Andrews, L. A. Conroy, R. May, I. Anderson, et al. A Potent Human Anti-Eotaxin1 Antibody, CAT-213: Isolation by Phage Display and in Vitro and in Vivo Efficacy J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1395 - 1404. [Abstract] [Full Text] [PDF] L. A. Beck, B. Tancowny, M. E. Brummet, S. Y. Asaki, S. L. Curry, M. B. Penno, M. Foster, A. Bahl, and C. Stellato Functional Analysis of the Chemokine Receptor CCR3 on Airway Epithelial Cells. J. Immunol., September 1, 2006; 177(5): 3344 - 3354. [Abstract] [Full Text] [PDF] T. Mateo, Y. Naim Abu Nabah, M. Abu Taha, M. Mata, M. Cerda-Nicolas, A. E. I. Proudfoot, R. A. K. Stahl, A. C. Issekutz, J. Cortijo, E. J. Morcillo, et al. Angiotensin II-Induced Mononuclear Leukocyte Interactions with Arteriolar and Venular Endothelium Are Mediated by the Release of Different CC Chemokines J. Immunol., May 1, 2006; 176(9): 5577 - 5586. [Abstract] [Full Text] [PDF] B. O. Abonyo, M. S. Alexander, and A. S. Heiman Autoregulation of CCL26 synthesis and secretion in A549 cells: a possible mechanism by which alveolar epithelial cells modulate airway inflammation Am J Physiol Lung Cell Mol Physiol, September 1, 2005; 289(3): L478 - L488. [Abstract] [Full Text] [PDF] P. C. Fulkerson, H. Zhu, D. A. Williams, N. Zimmermann, and M. E. Rothenberg CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism Blood, July 15, 2005; 106(2): 436 - 443. [Abstract] [Full Text] [PDF] S. Paoletti, V. Petkovic, S. Sebastiani, M. G. Danelon, M. Uguccioni, and B. O. Gerber A rich chemokine environment strongly enhances leukocyte migration and activities Blood, May 1, 2005; 105(9): 3405 - 3412. [Abstract] [Full Text] [PDF] S. P. Matthews, J. S. Tregoning, A. J. Coyle, T. Hussell, and P. J. M. Openshaw Role of CCL11 in Eosinophilic Lung Disease during Respiratory Syncytial Virus Infection J. Virol., February 15, 2005; 79(4): 2050 - 2057. [Abstract] [Full Text] [PDF] R. L. Jones, N. J. Hannan, T. J. Kaitu'u, J. Zhang, and L. A. Salamonsen Identification of Chemokines Important for Leukocyte Recruitment to the Human Endometrium at the Times of Embryo Implantation and Menstruation J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6155 - 6167. [Abstract] [Full Text] [PDF] B Moser and K Willimann Chemokines: role in inflammation and immune surveillance Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii84 - ii89. [Abstract] [Full Text] [PDF] V. Petkovic, C. Moghini, S. Paoletti, M. Uguccioni, and B. Gerber I-TAC/CXCL11 is a natural antagonist for CCR5 J. Leukoc. Biol., September 1, 2004; 76(3): 701 - 708. [Abstract] [Full Text] [PDF] P. Ogilvie, S. Thelen, B. Moepps, P. Gierschik, A. C. da Silva Campos, M. Baggiolini, and M. Thelen Unusual Chemokine Receptor Antagonism Involving a Mitogen-Activated Protein Kinase Pathway J. Immunol., June 1, 2004; 172(11): 6715 - 6722. [Abstract] [Full Text] [PDF] V. Petkovic, C. Moghini, S. Paoletti, M. Uguccioni, and B. Gerber Eotaxin-3/CCL26 Is a Natural Antagonist for CC Chemokine Receptors 1 and 5: A HUMAN CHEMOKINE WITH A REGULATORY ROLE J. Biol. Chem., May 28, 2004; 279(22): 23357 - 23363. [Abstract] [Full Text] [PDF] E. K. Lau, C. D. Paavola, Z. Johnson, J.-P. Gaudry, E. Geretti, F. Borlat, A. J. Kungl, A. E. Proudfoot, and T. M. Handel Identification of the Glycosaminoglycan Binding Site of the CC Chemokine, MCP-1: IMPLICATIONS FOR STRUCTURE AND FUNCTION IN VIVO J. Biol. Chem., May 21, 2004; 279(21): 22294 - 22305. [Abstract] [Full Text] [PDF] V. J. Erpenbeck, A. Hagenberg, Y. Dulkys, J. Elsner, R. Balder, H. Krentel, M. Discher, A. Braun, N. Krug, and J. M. Hohlfeld Natural Porcine Surfactant Augments Airway Inflammation after Allergen Challenge in Patients with Asthma Am. J. Respir. Crit. Care Med., March 1, 2004; 169(5): 578 - 586. [Abstract] [Full Text] [PDF] P. C. Fulkerson, N. Zimmermann, E. B. Brandt, E. E. Muntel, M. P. Doepker, J. L. Kavanaugh, A. Mishra, D. P. Witte, H. Zhang, J. M. Farber, et al. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-{gamma} (Mig, CXCL9) PNAS, February 17, 2004; 101(7): 1987 - 1992. [Abstract] [Full Text] [PDF] B. Jaruga, F. Hong, R. Sun, S. Radaeva, and B. Gao Crucial Role of IL-4/STAT6 in T Cell-Mediated Hepatitis: Up-Regulating Eotaxins and IL-5 and Recruiting Leukocytes J. Immunol., September 15, 2003; 171(6): 3233 - 3244. [Abstract] [Full Text] [PDF] P. Ogilvie, S. Paoletti, I. Clark-Lewis, and M. Uguccioni Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes Blood, August 1, 2003; 102(3): 789 - 794. [Abstract] [Full Text] [PDF] M. Kleinhans, A. Tun-Kyi, M. Gilliet, M. E. Kadin, R. Dummer, G. Burg, and F. O. Nestle Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma Blood, February 15, 2003; 101(4): 1487 - 1493. [Abstract] [Full Text] [PDF] C. Pastore, G. R. Picchio, F. Galimi, R. Fish, O. Hartley, R. E. Offord, and D. E. Mosier Two Mechanisms for Human Immunodeficiency Virus Type 1 Inhibition by N-Terminal Modifications of RANTES Antimicrob. Agents Chemother., February 1, 2003; 47(2): 509 - 517. [Abstract] [Full Text] [PDF] I. Clark-Lewis, I. Mattioli, J.-H. Gong, and P. Loetscher Structure-Function Relationship between the Human Chemokine Receptor CXCR3 and Its Ligands J. Biol. Chem., January 3, 2003; 278(1): 289 - 295. [Abstract] [Full Text] [PDF] S. Beaulieu, D. F. Robbiani, X. Du, E. Rodrigues, R. Ignatius, Y. Wei, P. Ponath, J. W. Young, M. Pope, R. M. Steinman, et al. Expression of a Functional Eotaxin (CC Chemokine Ligand 11) Receptor CCR3 by Human Dendritic Cells J. Immunol., September 15, 2002; 169(6): 2925 - 2936. [Abstract] [Full Text] [PDF] A. Menzies-Gow, S. Ying, I. Sabroe, V. L. Stubbs, D. Soler, T. J. Williams, and A. B. Kay Eotaxin (CCL11) and Eotaxin-2 (CCL24) Induce Recruitment of Eosinophils, Basophils, Neutrophils, and Macrophages As Well As Features of Early- and Late-Phase Allergic Reactions Following Cutaneous Injection in Human Atopic and Nonatopic Volunteers J. Immunol., September 1, 2002; 169(5): 2712 - 2718. [Abstract] [Full Text] [PDF] R. Martinelli, I. Sabroe, G. LaRosa, T. J. Williams, and J. E. Pease The CC Chemokine Eotaxin (CCL11) Is a Partial Agonist of CC Chemokine Receptor 2b J. Biol. Chem., November 9, 2001; 276(46): 42957 - 42964. [Abstract] [Full Text] [PDF] F. R. Fischer, Y. Luo, M. Luo, L. Santambrogio, and M. E. Dorf RANTES-Induced Chemokine Cascade in Dendritic Cells J. Immunol., August 1, 2001; 167(3): 1637 - 1643. [Abstract] [Full Text] [PDF] P. Loetscher and I. Clark-Lewis Agonistic and antagonistic activities of chemokines J. Leukoc. Biol., June 1, 2001; 69(6): 881 - 884. [Abstract] [Full Text] [PDF] C. Bandeira-Melo, A. Herbst, and P. F. Weller Eotaxins . Contributing to the Diversity of Eosinophil Recruitment and Activation Am. J. Respir. Cell Mol. Biol., June 1, 2001; 24(6): 653 - 657. [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ogilvie, P. Articles by Uguccioni, M. Search for Related Content PubMed PubMed Citation Articles by Ogilvie, P. Articles by Uguccioni, M. Related Collections Phagocytes Chemokines, Cytokines, and Interleukins Social Bookmarking                   What's this?

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020